Envoy Medical, INC 10-Q quarterly reports

Envoy Medical, Inc. filed its Q2 2026 Form 10-Q, detailing continued net losses and progress in its Acclaim CI clinical trials, while facing substantial doubt regarding its going concern status.

Envoy Medical, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, progress on its Acclaim CI product, and ongoing operational challenges.

Envoy Medical reported increased net losses in Q3 2025, but advanced its pivotal Acclaim CI clinical trial and raised significant capital through offerings and warrant exercises, while addressing Nasdaq compliance and internal control weaknesses.

Envoy Medical, a hearing health company, reported increased net losses and a growing accumulated deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its Acclaim CI clinical trials.

Envoy Medical reports a net loss for Q1 2025, but highlights progress with its Acclaim Cochlear Implant clinical trial and ongoing development efforts.

Envoy Medical obtained a $10 million loan from GAT Funding, while reporting a net loss for Q3 2024 and providing updates on its Acclaim CI clinical trial progress.

Envoy Medical reports a net loss of $10.2 million for the first half of 2024, while advancing the development of its Acclaim Cochlear Implant.

Envoy Medical obtained a $10 million loan and reported a net loss of $6.27 million for the first quarter of 2024, while advancing its Acclaim cochlear implant development.

Envoy Medical has restated its third-quarter 2023 financial statements due to an error in the accounting treatment of a forward purchase agreement.